EW240920P70000
- 3.10
- +1.17+60.62%
Edwards Lifesciences Newsroom
Express News | Edwards Lifesciences Corp Shares Hit Session Low, Falling Sharply in Afternoon Volume Pickup, Last Down 1.7% at $68.11
Edwards Launches SAPIEN 3 With Alterra Prestent in Europe for Transcatheter Pulmonic Valve Implantation
Watching Edwards Lifesciences; Traders Circulate Unconfirmed M&A Blog Comments Suggesting The Co Is Engaged In Takeover Chatter
BofA Securities Downgrades Edwards Lifesciences(EW.US) to Hold Rating, Cuts Target Price to $75
BofA Securities analyst Travis Steed downgrades $Edwards Lifesciences(EW.US)$ to a hold rating, and adjusts the target price from $105 to $75.According to TipRanks data, the analyst has a success
Unusual Options Activity: ETSY, SWKS and Others Attract Market Bets, ETSY V/OI Ratio Reaches 119.8
EST Sep 13th Morning Delivery - In the last two hours of trading, 8 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Truist Financial Downgrades Edwards Lifesciences(EW.US) to Hold Rating
Truist Financial analyst Richard Newitter downgrades $Edwards Lifesciences(EW.US)$ to a hold rating.According to TipRanks data, the analyst has a success rate of 58.8% and a total average return of 16
Truist Financial Sticks to Its Hold Rating for Edwards Lifesciences (EW)
Express News | Edwards Lifesciences Corp : Truist Securities Cuts Target Price to $71 From $82
How Is Edwards Lifesciences' Stock Performance Compared to Other Medical Devices Stocks?
Three 'Buys,' Three 'Sells,' and a 'Hold,' by Oppenheimer Analysts
Edwards Lifesciences Price Target Maintained With a $90.00/Share by Oppenheimer
Oppenheimer Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $90
Oppenheimer analyst Suraj Kalia maintains $Edwards Lifesciences(EW.US)$ with a buy rating, and maintains the target price at $90.According to TipRanks data, the analyst has a success rate of 53.2%
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), MoonLake Immunotherapeutics (MLTX) and Protara Therapeutics (TARA)
Some Edwards Lifesciences Corporation (NYSE:EW) Analysts Just Made A Major Cut To Next Year's Estimates
UBS Maintains Neutral on Edwards Lifesciences, Lowers Price Target to $75
UBS Maintains Edwards Lifesciences(EW.US) With Hold Rating, Cuts Target Price to $75
UBS analyst Danielle Antalffy maintains $Edwards Lifesciences(EW.US)$ with a hold rating, and adjusts the target price from $90 to $75.According to TipRanks data, the analyst has a success rate of 51.
Barclays Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $80
Barclays analyst Matt Miksic maintains $Edwards Lifesciences(EW.US)$ with a buy rating, and maintains the target price at $80.According to TipRanks data, the analyst has a success rate of 61.9% and
Edwards Lifesciences Is Maintained at Overweight by Wells Fargo
Edwards Lifesciences Analyst Ratings
Wells Fargo Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $80
Wells Fargo analyst Larry Biegelsen maintains $Edwards Lifesciences(EW.US)$ with a buy rating, and maintains the target price at $80.According to TipRanks data, the analyst has a success rate of 62.6%